NAD recommends Lunada tone down claims for menopausal supplement

NEW YORK — The National Advertising Division of the Council of Better Business Bureaus on Wednesday recommended Lunada Biomedical modify or discontinue a certain range of advertising claims for Amberen, a dietary supplement promoted to menopausal women.



NAD noted in its decision that Lunada had voluntarily discontinued certain claims, including claims that relief is "complete," "fast," that Amberen is an "all-in-one solution," and that Amberen can achieve "balanced production and circulation of hormones throughout your body" and support "the optimal function of your vital organs. Energy metabolism is soon restored. Suddenly you feel younger!"



NAD also noted Lunada’s decision to discontinue making its claim that the ingredients in Amberen are on the Food and Drug Administration’s Generally Recognized as Safe list.



NAD shared several concerns around the disconnect between a study purportedly supporting Lunada's claims and the advertising at issue. NAD recommended that Lunada discontinue claims that Amberen relieves "night sweats," "moodiness" and "inability to concentrate." Further, NAD cautioned the advertiser against suggesting or implying that the product provides complete or near-complete relief of symptoms.



NAD determined the company could support claims related to its proprietary technology, as well as the claim that Amberen could lessen various symptoms of menopause.

 

NAD is an investigative unit of the advertising industry’s system of self-regulation and administered by the Council of Better Business Bureaus. As a part of its ongoing monitoring program and in conjunction with NAD’s initiative with the Council for Responsible Nutrition designed to expand review of advertising claims for dietary supplements, NAD requested the advertiser provide substantiation for claims made in print and Internet advertising.

Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.